| Oct 2 |
Psyence Biomedical files to sell 10.9M common shares for holders
|
| Sep 20 |
Psyence Group Enters into Agreement to Dispose of Stake in PsyLabs
|
| Sep 19 |
Psyence Biomed Enters into Agreement to Acquire Stake in PsyLabs
|
| Sep 18 |
Psyence Group's NASDAQ-Listed Associate, Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones
|
| Sep 16 |
Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket
|
| Sep 9 |
Psyence Biomed Launches First Trial Site In Australia For Phase IIb Psilocybin Study In Palliative Care
|
| Sep 9 |
Psyence Biomed Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care
|
| Sep 6 |
Psyence Biomedical to acquire drug developer Clairvoyant
|
| Sep 6 |
Psyence Biomed Announces the Signing of a Conditional Binding Term Sheet for the Acquisition of Psilocybin-Based Drug Developer Clairvoyant
|
| Aug 30 |
Psyence Biomed Announces Registration Statement on Form F-1 for Up to $25 Million Equity Line of Credit with White Lion Capital, LLC, Declared Effective by SEC
|
